Identification of the site of binding of sulfated, low molecular weight lignins on thrombin

Biochemical and Biophysical Research Communications

Volumn 413, Issue 2, 2011, Pages 348-352

  Abdel Aziz, May H ^a   Mosier, Philip D ^a   Desai, Umesh R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Allosteric inhibitors; Enzyme inhibition; Factor Xa; Heparin mimetics; Thrombin

Indexed keywords

ALANINE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9A; CDSO3; LIGNIN; LOW MOLECULAR WEIGHT LIGNIN; RECOMBINANT THROMBIN; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; COMPARATIVE STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG EFFICACY; DRUG SYNTHESIS; IC 50; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LIGNIN; MOLECULAR WEIGHT; MUTAGENESIS, SITE-DIRECTED; SULFATES; THROMBIN;

EID: 80053109628     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.08.102     Document Type: Article

References (21)

1. Olson S.T., Chuang Y.J. Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. Trends Cardiovasc. Med. 2002, 12:331-338.
2. Henry B.L., Desai U.R. Anticoagulants. Drug Discovery and Development 2010, 365-408. John Wiley and Sons, NY. seventh ed. D. Rotella, D.J. Abraham (Eds.).
3. Olson S.T., Swanson R., Raub-Segall E., Bedsted T., Sadri M., Petitou M., Herault J.P., Herbert J.M., Bjork I. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin. Thromb. Haemost. 2004, 92:929-939.
4. Hirsh J., Anand S.S., Halperin J.L., Fuster V. Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation 2001, 103:2994-3018.
5. Hirsh J., Fuster V., Ansell J., Halperin J.L. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003, 107:1692-1711.
6. Monien B.H., Henry B.L., Raghuraman A., Hindle M., Desai U.R. Novel chemo-enzymatic oligomers of cinnamic acids as direct and indirect inhibitors of coagulation proteinases. Bioorg. Med. Chem. 2006, 14:7988-7998.
7. Henry B.L., Monien B.H., Bock P.E., Desai U.R. A novel allosteric pathway of thrombin inhibition. Exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids. J. Biol. Chem. 2007, 282:31891-31899.
8. Henry B.L., Thakkar J.N., Martin E.J., Brophy D.F., Desai U.R. Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids. Blood Coagul. Fibrinolysis 2009, 20:27-34.
9. Liang A., Thakkar J.N., Desai U.R. Study of physico-chemical properties of novel highly sulfated, aromatic, mimetics of heparin and heparan sulfate. J. Pharm. Sci. 2010, 99:1207-1216.
10. Henry B.L., Desai U.R. Recent research developments in the direct inhibition of coagulation proteinases: inhibitors of the initiation phase. Cardiovasc. Haematol. Agents Med. Chem. 2008, 6:323-336.
11. Henry B.L., Abdel Aziz M., Zhou Q., Desai U.R. Sulfated, low molecular weight lignins are potent inhibitors of plasmin, in addition to thrombin and factor Xa: novel opportunity for controlling complex pathologies. Thromb. Haemost. 2010, 103:507-515.
12. He X., Ye Y., Esmon C.T., Rezaie A.R. Influence of arginines 93, 97, and 101 of thrombin to its functional specificity. Biochemistry 1997, 36:8969-8976.
13. Yang L., Rezaie A.R. Calcium-binding sites of the thrombin-thrombomodulin-protein C complex: possible implications for the effect of platelet factor 4 on the activation of vitamin K-dependent coagulation factors. Thromb. Haemost. 2007, 97:899-906.
14. Larkin M.A., Blackshields G., Brown N.P., Chenna R., McGettigan P.A., McWilliam H., Valentin F., Wallace I.M., Wilm A., Lopez R., Thompson J.D., Gibson T.J., Higgins D.G. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23:2947-2948.
15. Bode W., Mayr I., Baumann U., Huber R., Stone S.R., Hofsteenge J. The refined 1.9A crystal structure of human alpha-thrombin: interaction with d-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989, 8:3467-3475.
16. Burford N.T., Watson J., Bertekap R., Alt A. Strategies for the identification of allosteric modulators of G-protein-coupled receptors. Biochem. Pharmacol. 2011, 81:691-702.
17. Di Cera E. Thrombin as an anticoagulant. Prog. Mol. Biol. Trans. Sci. 2011, 99:145-184.
18. J.A. Huntington, Thrombin plasticity, Biochim. Biophys. Acta, in press, doi:10.1016/j.bbapap.2011.07.005.
19. Carter W.J., Cama E., Huntington J.A. Crystal structure of thrombin bound to heparin. J. Biol. Chem. 2005, 280:2745-2749.
20. Tsiang M., Jain A.K., Gibbs C.S. Functional requirements for inhibition of thrombin by antithrombin III in the presence and absence of heparin. J. Biol. Chem. 1997, 272:12024-12029.
21. Desai B.J., Boothello R., Mehta A.Y., Scarsdale J.N., Wright H.T., Desai U.R. Interaction of thrombin with sucrose octasulfate. Biochemistry 2011, 50:6973-6982.